Q1 2024 EPS Estimates for Keros Therapeutics, Inc. (NASDAQ:KROS) Lifted by William Blair

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities researchers at William Blair raised their Q1 2024 EPS estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Wednesday, March 27th. William Blair analyst M. Phipps now anticipates that the company will post earnings of ($1.25) per share for the quarter, up from their previous estimate of ($1.26). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.11) per share.

Other analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Friday, March 1st. Wedbush reissued an “outperform” rating and set a $86.00 target price on shares of Keros Therapeutics in a research report on Thursday, February 29th. Wells Fargo & Company initiated coverage on shares of Keros Therapeutics in a research report on Friday, December 8th. They set an “overweight” rating and a $60.00 target price on the stock. Piper Sandler reissued an “overweight” rating and set a $105.00 target price on shares of Keros Therapeutics in a research report on Wednesday. Finally, Truist Financial reissued a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Wednesday, March 13th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $86.00.

Keros Therapeutics Trading Up 2.4 %

NASDAQ KROS opened at $66.20 on Friday. The company has a 50 day moving average price of $61.61 and a 200 day moving average price of $43.91. Keros Therapeutics has a 52 week low of $27.02 and a 52 week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Friday, March 1st. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $0.14 million during the quarter. During the same period in the prior year, the company posted ($1.09) EPS.

Institutional Trading of Keros Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC grew its position in Keros Therapeutics by 7.1% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,743 shares of the company’s stock valued at $109,000 after buying an additional 182 shares during the period. Wellington Management Group LLP grew its position in Keros Therapeutics by 1.2% during the first quarter. Wellington Management Group LLP now owns 18,984 shares of the company’s stock valued at $1,032,000 after buying an additional 227 shares during the period. California State Teachers Retirement System grew its position in Keros Therapeutics by 1.9% during the third quarter. California State Teachers Retirement System now owns 19,511 shares of the company’s stock valued at $734,000 after buying an additional 364 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Keros Therapeutics by 3.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,898 shares of the company’s stock valued at $513,000 after buying an additional 404 shares during the period. Finally, Amalgamated Bank grew its position in Keros Therapeutics by 15.6% during the fourth quarter. Amalgamated Bank now owns 3,245 shares of the company’s stock valued at $156,000 after buying an additional 439 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.